Aegerion sinks on 3Q Juxtapid sales, forecast
This article was originally published in Scrip
Executive Summary
Aegerion Pharmaceuticals sank 41% to $20.19 per share on 31 October after the company revealed lower than expected third quarter sales and cut its full-year 2014 sales guidance due to increased discontinuation rates for Juxtapid (lomitapide) and reimbursement challenges in ex-US markets.